Global Blood Therapeutics (GBT) Misses Q4 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts GBT Hot Sheet
Price: $68.49 --0%
Financial Fact:
Comprehensive Income: 13.72M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Comprehensive Income: 13.72M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Global Blood Therapeutics (NASDAQ: GBT) reported Q4 EPS of ($1.36), $0.23 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $56.1 million versus the consensus estimate of $55.44 million.
For earnings history and earnings-related data on Global Blood Therapeutics (GBT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Infosys Limited (INFY) Reports In-Line Q3 EPS
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
